The invention relates to a process for solution-phase synthesis of D-Arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide, an active ingredient used for both common and rare diseases including a mitochondrial targeted therapy for ischemia reperfusion injury.

The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.

The object of the present invention relates to a novel family of peptide conjugates of formula (I):

A-X.sub.1-X.sub.2-Pro-Ala-X-B(I) wherein: A represents a hydrogen atom, a C.sub.6 to C.sub.20 acyl group or a cholesterol residue; X.sub.1 represents a covalent bond, an alanine or a proline; X.sub.2 represents an arginine, a lysine, or an alanine; X represents a lysine, an alanine, or a phenylalanine; and B represents a hydroxyl or an amine; or one of its preferentially pharmaceutically, dermatologically or cosmetically acceptable salts,

as well as their synthesis processes and their uses for reducing hair loss and stimulating hair growth.

The present invention discloses crosslinked poly(alkylene glycol) (PAG)-based hydrogel compositions, systems containing a plurality of cancer cells in contact with a cell culture media and encapsulated in the crosslinked PAG-based hydrogel composition and methods of making such crosslinked hydrogel compositions and systems. Also disclosed herein are methods of using such compositions and systems, such as, for example for screening an agent for effectiveness of the agent against cancer cells. Also disclosed herein are kits containing one or more components including one or more systems of the present disclosure and one or more instructions.

The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.

The disclosure provides methods of preventing or treating heart failure in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof.

Disclosed are various crystalline salt forms of Boc-D-Arg-DMT-Lys(Boc)-Phe-NH.sub.2.

Antimicrobial peptides and methods of use are provided.

The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.

The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.